Aditxt, Inc. (NASDAQ: ADTX) Announces 1-for-40 Reverse Stock Split Effective at the Open of Trading on October 2, 2024
27 September 2024 - 2:15PM
Business Wire
Aditxt, Inc. (NASDAQ: ADTX) (“Aditxt” or the “Company”), an
innovation platform dedicated to accelerating promising health
innovations, announced today that it will effect a 1-for-40 reverse
split of its common stock. Commencing with the opening of trading
on the Nasdaq Capital Market on October 2, 2024, the Company’s
common stock will trade on a post-split basis under the same symbol
ADTX. The reverse stock split was approved by the Company’s
stockholders at the annual meeting held on August 7, 2024, with the
final ratio determined by the Company’s board of directors.
As a result of the reverse stock split, the CUSIP number for the
Company’s common stock will now be 007025703. As a result of the
reverse stock split, every 40 shares of issued and outstanding
common stock will be exchanged for 1 share of common stock, with
any fractional shares being rounded up to the next higher whole
share. Immediately after the reverse stock split becomes effective,
the Company will have approximately 244,667 shares of common stock
issued and outstanding.
The reverse stock split is primarily intended to bring the
Company into compliance with Nasdaq’s minimum bid price
requirement.
Additional information concerning the reverse stock split can be
found in Aditxt’s definitive proxy statement filed with the
Securities and Exchange Commission on July 5, 2024, as amended.
About Aditxt, Inc.
Aditxt, Inc.® is an innovation platform dedicated to
accelerating promising health innovations. Aditxt’s ecosystem of
research institutions, industry partners, and shareholders
collaboratively drives their mission to "Make Promising Innovations
Possible Together." The innovation platform is the cornerstone of
Aditxt’s strategy, where multiple disciplines drive disruptive
growth and address significant societal challenges. Aditxt operates
a unique model that democratizes innovation, ensures every
stakeholder’s voice is heard and valued, and empowers collective
progress.
Aditxt currently operates two programs focused on immune health
and precision health. The Company plans to introduce two additional
programs dedicated to public health and women’s health. For these,
Aditxt has entered into an Arrangement Agreement with Appili
Therapeutics, Inc. (“Appili”) (TSX: APLI; OTCPink: APLIF), which
focuses on infectious diseases, and a Merger Agreement with Evofem
Biosciences, Inc. (“Evofem”) (OTCQB: EVFM). Each program will be
designed to function autonomously while collectively advancing
Aditxt’s mission of discovering, developing, and deploying
innovative health solutions to tackle some of the most urgent
health challenges. The closing of each of the transactions with
Appili and Evofem is subject to several conditions, including but
not limited to approval of the transactions by the respective
target shareholders and Aditxt raising sufficient capital to fund
its obligations at closing. No assurance can be provided that all
of the conditions to closing will be obtained or satisfied or that
either of the transactions will ultimately close.
For more information, www.aditxt.com.
Follow us on: LinkedIn: https://www.linkedin.com/company/aditxt
Facebook: https://www.facebook.com/aditxtplatform/
Forward-Looking Statements
Certain statements in this press release constitute
“forward-looking statements” within the meaning of federal
securities laws. Forward-looking statements include statements
regarding the Company’s intentions, beliefs, projections, outlook,
analyses, or current expectations concerning, among other things,
the Company’s ongoing and planned product and business development;
the Company’s ability to finance and execute its strategic M&A
initiatives; the Company’s ability to obtain the necessary funding
and partner to commence clinical trials; the Company’s intellectual
property position; the Company’s ability to develop commercial
functions; expectations regarding product launch and revenue; the
Company’s results of operations, cash needs, spending, financial
condition, liquidity, prospects, growth, and strategies; the
Company’s ability to raise additional capital; the industry in
which the Company operates; and the trends that may affect the
industry or the Company. Forward-looking statements are not
guarantees of future performance, and actual results may differ
materially from those indicated by these forward-looking statements
as a result of various important factors, as well as market and
other conditions and those risks more fully discussed in the
section titled “Risk Factors” in Aditxt’s most recent Annual Report
on Form 10-K, as well as discussions of potential risks,
uncertainties, and other important factors in the Company’s other
filings with the Securities and Exchange Commission. All such
statements speak only as of the date made, and the Company
undertakes no obligation to update or revise publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20240927965823/en/
Aditxt, Inc. Mary O’Brien Mobrien@aditxt.com
516-753-9933
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
Von Sep 2024 bis Okt 2024
Aditxt (NASDAQ:ADTX)
Historical Stock Chart
Von Okt 2023 bis Okt 2024